S

Sage Therapeutics
D

SAGE

7.02500
USD
0.08
(1.08%)
Market Closed
Volume
55,009
EPS
-4
Div Yield
-
P/E
-1
Market Cap
429,742,173
Related Instruments
    C
    CLLS
    0.05000
    (3.36%)
    1.54000 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    F
    FOLD
    0.03500
    (0.37%)
    9.54500 USD
    Q
    QURE
    0.390
    (2.61%)
    15.310 USD
    R
    RCKT
    0.320
    (3.15%)
    10.490 USD
    More
News

Title: Sage Therapeutics

Sector: Healthcare
Industry: Biotechnology
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.